CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Paratek Pharma - PRTK CFD

    2.22
    2.3%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.05
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026235 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026235%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.004012 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.004012%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Paratek Pharmaceuticals Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 2.17
    Open* 2.17
    1-Year Change* -12.15%
    Day's Range* 2.17 - 2.22
    52 wk Range 1.29-3.65
    Average Volume (10 days) 341.85K
    Average Volume (3 months) 11.48M
    Market Cap 127.26M
    P/E Ratio -100.00K
    Shares Outstanding 57.32M
    Revenue 177.00M
    EPS -1.11
    Dividend (Yield %) N/A
    Beta 1.69
    Next Earnings Date Nov 1, 2023

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Sep 20, 2023 2.22 0.05 2.30% 2.17 2.22 2.17
    Sep 19, 2023 2.17 0.00 0.00% 2.17 2.17 2.16
    Sep 18, 2023 2.16 -0.01 -0.46% 2.17 2.18 2.16
    Sep 15, 2023 2.17 -0.01 -0.46% 2.18 2.18 2.16
    Sep 14, 2023 2.17 -0.01 -0.46% 2.18 2.18 2.17
    Sep 13, 2023 2.18 -0.01 -0.46% 2.19 2.19 2.18
    Sep 12, 2023 2.19 0.00 0.00% 2.19 2.19 2.19
    Sep 11, 2023 2.18 -0.01 -0.46% 2.19 2.20 2.18
    Sep 8, 2023 2.19 0.01 0.46% 2.18 2.19 2.18
    Sep 7, 2023 2.19 0.01 0.46% 2.18 2.19 2.18
    Sep 6, 2023 2.18 0.01 0.46% 2.17 2.19 2.17
    Sep 5, 2023 2.18 0.01 0.46% 2.17 2.19 2.17
    Sep 1, 2023 2.17 -0.02 -0.91% 2.19 2.20 2.17
    Aug 31, 2023 2.19 0.02 0.92% 2.17 2.19 2.17
    Aug 30, 2023 2.18 0.01 0.46% 2.17 2.20 2.17
    Aug 29, 2023 2.18 0.01 0.46% 2.17 2.18 2.17
    Aug 28, 2023 2.17 0.01 0.46% 2.16 2.18 2.16
    Aug 25, 2023 2.18 0.01 0.46% 2.17 2.19 2.17
    Aug 24, 2023 2.18 0.02 0.93% 2.16 2.18 2.16
    Aug 23, 2023 2.16 0.00 0.00% 2.16 2.16 2.16

    Paratek Pharma Events

    Time (UTC) Country Event
    Thursday, March 14, 2024

    Time (UTC)

    12:30

    Country

    US

    Event

    Q4 2023 Paratek Pharmaceuticals Inc Earnings Release
    Q4 2023 Paratek Pharmaceuticals Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 160.268 130.162 46.924 16.544 17.117
    Revenue 160.268 130.162 46.924 16.544 17.117
    Total Operating Expense 206.477 171.292 124.796 132.173 121.202
    Selling/General/Admin. Expenses, Total 145.398 119.004 89.355 89.135 63.658
    Research & Development 37.823 30.353 23.922 39.554 57.508
    Interest Expense (Income) - Net Operating 0 -0.071
    Unusual Expense (Income) 0 2.368 0 0.107
    Operating Income -46.209 -41.13 -77.872 -115.629 -104.085
    Interest Income (Expense), Net Non-Operating -17.367 -17.342 -18.725 -12.829 -7.725
    Other, Net 0.067 -0.012 0.056 -0.031 -0.044
    Net Income Before Taxes -63.509 -58.484 -96.541 -128.489 -111.854
    Net Income After Taxes -63.566 -59.084 -96.541 -128.79 -112.356
    Net Income Before Extra. Items -63.566 -59.084 -96.541 -128.79 -112.356
    Net Income -63.566 -59.084 -96.541 -128.79 -112.356
    Total Adjustments to Net Income
    Income Available to Common Excl. Extra. Items -63.566 -59.084 -96.541 -128.79 -112.356
    Income Available to Common Incl. Extra. Items -63.566 -59.084 -96.541 -128.79 -112.356
    Diluted Net Income -63.566 -59.084 -96.541 -128.79 -112.356
    Diluted Weighted Average Shares 54.3879 48.4155 44.1748 32.7919 31.5135
    Diluted EPS Excluding Extraordinary Items -1.16875 -1.22035 -2.18543 -3.92749 -3.56533
    Diluted Normalized EPS -1.16875 -1.22035 -2.13183 -3.92749 -3.56313
    Cost of Revenue, Total 23.056 21.535 8.651 3.484
    Gross Profit 137.212 108.627 38.273 13.06
    Depreciation / Amortization 0.2 0.4 0.5
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 39.993 31.236 75.557 30.213 29.637
    Revenue 39.993 31.236 75.557 30.213 29.637
    Cost of Revenue, Total 4.368 6.244 10.312 4.372 4.878
    Gross Profit 35.625 24.992 65.245 25.841 24.759
    Total Operating Expense 49.404 47.041 78.394 46.704 42.805
    Selling/General/Admin. Expenses, Total 36.264 33.489 53.814 33.846 30.335
    Research & Development 8.772 7.308 14.268 8.486 7.592
    Operating Income -9.411 -15.805 -2.837 -16.491 -13.168
    Interest Income (Expense), Net Non-Operating -5.035 -4.255 -4.231 -4.35 -4.413
    Other, Net -0.056 -0.022 -0.032 -0.039 -0.038
    Net Income Before Taxes -14.502 -20.082 -7.1 -20.88 -17.619
    Net Income After Taxes -14.553 -20.143 -7.157 -20.88 -17.619
    Net Income Before Extra. Items -14.553 -20.143 -7.157 -20.88 -17.619
    Net Income -14.553 -20.143 -7.157 -20.88 -17.619
    Income Available to Common Excl. Extra. Items -14.553 -20.143 -7.157 -20.88 -17.619
    Income Available to Common Incl. Extra. Items -14.553 -20.143 -7.157 -20.88 -17.619
    Diluted Net Income -14.553 -20.143 -7.157 -20.88 -17.619
    Diluted Weighted Average Shares 57.2822 56.9034 55.7513 55.1665 53.0233
    Diluted EPS Excluding Extraordinary Items -0.25406 -0.35399 -0.12837 -0.37849 -0.33229
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.25406 -0.35399 -0.12837 -0.37849 -0.33229
    Unusual Expense (Income)
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 136.842 152.1 164.117 243.354 255.243
    Cash and Short Term Investments 34.248 95.474 125.162 215.379 250.351
    Cash & Equivalents 34.248 80.367 105.157 102.302 46.987
    Short Term Investments 0 15.107 20.005 113.077 203.364
    Total Receivables, Net 78.038 33.117 15.733 9.583 0.249
    Accounts Receivable - Trade, Net 78.038 33.117 15.733 9.583 0.249
    Prepaid Expenses 7.866 12.364 7.776 6.489 4.377
    Other Current Assets, Total 0.125 0.125 0.891 0.324 0.266
    Total Assets 172.538 183.869 176.853 251.079 300.192
    Property/Plant/Equipment, Total - Net 2.398 2.551 2.974 3.741 1.173
    Property/Plant/Equipment, Total - Gross 4.874 4.814 5.761 6.077 2.985
    Accumulated Depreciation, Total -2.476 -2.263 -2.787 -2.336 -1.812
    Goodwill, Net 0.829 0.829 0.829 0.829 0.829
    Intangibles, Net 0
    Other Long Term Assets, Total 32.469 28.389 8.933 3.155 0.46
    Total Current Liabilities 37.388 31.297 23.953 24.2 17.709
    Accounts Payable 5.308 5.394 1.813 4.116 2.09
    Accrued Expenses 31.71 24.046 21.626 17.696 15.619
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 0.37 1.857 0.514 2.388
    Total Liabilities 343.58 311.656 279.113 290.726 252.614
    Total Long Term Debt 256.946 254.428 250.474 260.728 228.959
    Long Term Debt 256.946 254.428 250.474 260.728 228.959
    Other Liabilities, Total 49.246 25.931 4.686 5.798 5.946
    Total Equity -171.042 -127.787 -102.26 -39.647 47.578
    Preferred Stock - Non Redeemable, Net 0 0
    Common Stock 0.056 0.052 0.046 0.04 0.032
    Additional Paid-In Capital 759.351 739.053 705.489 671.497 630.142
    Retained Earnings (Accumulated Deficit) -930.449 -866.883 -807.799 -711.258 -582.468
    Other Equity, Total 0 -0.009 0.004 0.074 -0.128
    Total Liabilities & Shareholders’ Equity 172.538 183.869 176.853 251.079 300.192
    Total Common Shares Outstanding 56.6516 51.7118 46.5166 39.8278 32.2594
    Long Term Investments 0 42.487
    Total Inventory 16.565 11.02 14.555 11.579
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Total Current Assets 111.014 136.842 121.341 127.768 133.282
    Cash and Short Term Investments 45.026 34.248 57.009 69.391 79.053
    Cash & Equivalents 45.026 34.248 27.087 39.505 49.033
    Short Term Investments 0 29.922 29.886 30.02
    Total Receivables, Net 37.166 78.038 32.739 31.818 28.259
    Accounts Receivable - Trade, Net 37.166 78.038 32.739 31.818 28.259
    Total Inventory 13.989 16.565 20.75 13.083 12.732
    Prepaid Expenses 14.708 7.866 10.718 13.476 12.988
    Other Current Assets, Total 0.125 0.125 0.125 0 0.25
    Total Assets 150.828 172.538 157.321 163.695 170.157
    Property/Plant/Equipment, Total - Net 2.24 2.398 1.791 2.064 2.298
    Goodwill, Net 0.829 0.829 0.829 0.829 0.829
    Other Long Term Assets, Total 36.745 32.469 33.36 33.034 33.748
    Total Current Liabilities 32.745 37.388 38.976 30.1 28.837
    Accounts Payable 5.318 5.308 8.107 2.257 4.697
    Accrued Expenses 26.633 31.71 29.22 26.361 22.733
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 0.794 0.37 1.649 1.482 1.407
    Total Liabilities 339.866 343.58 323.473 313.062 310.459
    Total Long Term Debt 257.695 256.946 258.482 257.153 255.949
    Long Term Debt 257.695 256.946 258.482 257.153 255.949
    Other Liabilities, Total 49.426 49.246 26.015 25.809 25.673
    Total Equity -189.038 -171.042 -166.152 -149.367 -140.302
    Preferred Stock - Non Redeemable, Net 0 0 0 0 0
    Common Stock 0.057 0.056 0.055 0.055 0.053
    Additional Paid-In Capital 761.497 759.351 757.202 753.223 744.618
    Retained Earnings (Accumulated Deficit) -950.592 -930.449 -923.292 -902.412 -884.793
    Other Equity, Total 0 -0.117 -0.233 -0.18
    Total Liabilities & Shareholders’ Equity 150.828 172.538 157.321 163.695 170.157
    Total Common Shares Outstanding 57.2822 56.6516 55.4387 54.7786 53.0233
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -63.566 -59.084 -96.541 -128.79 -112.356
    Cash From Operating Activities -66.141 -48.273 -103.424 -134.045 -81.179
    Cash From Operating Activities 0.49 0.391 0.578
    Non-Cash Items 17.726 18.609 12.825 16.483 27.254
    Cash Interest Paid 11.91 13.144 22.703 15.96 9.31
    Changes in Working Capital -20.791 -8.189 -20.286 -21.738 3.923
    Cash From Investing Activities 14.804 4.51 92.499 134.554 -127.874
    Capital Expenditures -0.036 -0.373 -0.376 -0.239 -0.06
    Other Investing Cash Flow Items, Total 14.84 4.883 92.875 134.793 -127.814
    Cash From Financing Activities 5.093 18.332 11.34 57.622 220.727
    Financing Cash Flow Items 0.646
    Issuance (Retirement) of Stock, Net 7.335 19.048 22.623 27.068 51.803
    Issuance (Retirement) of Debt, Net -2.888 -0.716 -11.283 30.554 168.924
    Net Change in Cash -46.244 -25.431 0.415 58.131 11.674
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -20.143 -63.566 -56.409 -35.527 -17.91
    Cash From Operating Activities 11.09 -66.141 -46.028 -33.609 -19.11
    Cash From Operating Activities 0.047 0.49 0.404 0.275 0.144
    Non-Cash Items 3.175 17.726 14.39 9.079 3.99
    Cash Interest Paid 1.934 11.91 6.779 5.739 1.181
    Changes in Working Capital 28.011 -20.791 -4.413 -7.436 -5.334
    Cash From Investing Activities -0.032 14.804 -15.196 -15.196 -15.196
    Capital Expenditures -0.032 -0.036 -0.036 -0.036 -0.036
    Other Investing Cash Flow Items, Total 0 14.84 -15.16 -15.16 -15.16
    Cash From Financing Activities -0.28 5.093 7.819 7.818 3.097
    Issuance (Retirement) of Stock, Net 0 7.335 7.819 7.818 3.097
    Issuance (Retirement) of Debt, Net -0.28 -2.888 0 0 0
    Net Change in Cash 10.778 -46.244 -53.405 -40.987 -31.209
    Financing Cash Flow Items 0.646

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Paratek Pharma Company profile

    About Paratek Pharmaceuticals Inc

    Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel life-saving therapies for life-threatening diseases. The Company's product include NUZYRA (omadacycline) is an oral and intravenous antibiotic for the treatment of community-acquired bacterial pneumonia and acute skin and skin structure infections caused by susceptible pathogens. Its other product includes SEYSARA, which is a oral therapy for the treatment of moderate to severe acne vulgaris.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Paratek Pharmaceuticals Inc revenues increased from $46.9M to $130.2M. Net loss decreased 39% to $59.1M. Revenues reflect Product revenue, net increase from $38.8M to $106.1M, Collaboration and royalty revenue increase from $1.5M to $8.2M, Government contract grant revenue increase from $3.4M to $9.2M. Lower net loss reflects Interest Expense decrease of 14% to $17.4M (expense).

    Equity composition

    Common Stock $.001 Par, 3/11, 100M auth., 13,467,933 issd. Insiders control 9.22%. IPO: 5/06 .3M shs. @ $6.50 per share by Bear, Stearns & Co. Inc. 02/09, Name changed from Novacea, Inc. 02/09, 5-for-1 reverse stock split. 10/14,1-for-12 reverse stock split.

    Industry: Pharmaceuticals (NEC)

    75 Park Plaza
    4th Floor
    BOSTON
    MASSACHUSETTS 02116
    US

    Income Statement

    • Annual
    • Quarterly

    News

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023
    GBP

    UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?

    UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.

    10:48, 21 November 2023

    People also watch

    Gold

    2,072.25 Price
    +1.760% 1D Chg, %
    Long position overnight fee -0.0193%
    Short position overnight fee 0.0111%
    Overnight fee time 22:00 (UTC)
    Spread 0.30

    US100

    16,001.20 Price
    +0.470% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 7.0

    Oil - Crude

    74.50 Price
    -1.560% 1D Chg, %
    Long position overnight fee -0.0136%
    Short position overnight fee -0.0083%
    Overnight fee time 22:00 (UTC)
    Spread 0.040

    XRP/USD

    0.63 Price
    -0.120% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading